Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | THPO | P40225 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6716523 | 0.88 | NFKB1 (0.58) | ALDH1A1KDM4EMAPTNFKB1CYP1A2 | |
| SCHEMBL6717448 | 0.86 | TSHR (0.66) | ALDH1A1KDM4EMAPTNFKB1CYP1A2 | |
| SCHEMBL6714670 | 0.85 | NFKB1 (0.49) | ALDH1A1KDM4EMAPTNFKB1CYP1A2 | |
| SCHEMBL6718182 | 0.85 | ALDH1A1 (0.61) | ALDH1A1KDM4EMAPTNFKB1CYP1A2 | |
| SCHEMBL9317698 | 0.84 | TSHR (0.64) | ALDH1A1KDM4EMAPTNFKB1CYP1A2 | |
| SCHEMBL6714754 | 0.84 | TSHR (0.59) | ALDH1A1KDM4EMAPTNFKB1CYP1A2 | |
| SCHEMBL7292768 | 0.82 | NFKB1 (0.61) | ALDH1A1KDM4EMAPTNFKB1CYP1A2 | |
| SCHEMBL6720235 | 0.82 | NFKB1 (0.64) | ALDH1A1KDM4EMAPTNFKB1CYP1A2 | |
| SCHEMBL27676051 | 0.82 | NFKB1 (0.68) | ALDH1A1KDM4EMAPTNFKB1CYP1A2 | |
| SCHEMBL11043810 | 0.79 | ALDH1A1 (0.57) | ALDH1A1KDM4EMAPTNFKB1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2004-05-27 | — | — | US | claimed |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2003-11-27 | — | — | US | claimed |
| EP-0484437-A4 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | SEARLE & CO (US) | 1994-06-01 | — | — | EP | claimed |
| EP-0484437-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. Searle & Co. (US) | 1992-05-13 | — | — | EP | claimed |
| WO-1992001667-A1 | RENAL-SELECTIVE PRODRUGS FOR CONTROL OF RENAL SYMPATHETIC NERVE ACTIVITY IN THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-02-06 | — | — | WO | claimed |
| WO-1991001724-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1991-02-21 | — | — | WO | claimed |
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2004-05-27 | — | — | US | disclosed |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2003-11-27 | — | — | US | disclosed |
| EP-0484437-A4 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | SEARLE & CO (US) | 1994-06-01 | — | — | EP | disclosed |
| EP-0484437-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. Searle & Co. (US) | 1992-05-13 | — | — | EP | disclosed |
| WO-1991001724-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1991-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | GLS, APEH, GGH | ALDH1A1 100/4885KDM4E 1203/4885MAPT 1612/4885 |
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | GLS, DBH, APEH | ALDH1A1 114/4885KDM4E 935/4885MAPT 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.